BioWorld

Loud and clear: Sound Pharma has phase III success in Meniere’s

Sound Pharmaceuticals Inc.’s lead candidate, the anti-inflammatory SPI-1005 (ebselen), has produced positive pivotal phase III study data in treating Meniere’s disease, an inner-ear disorder that can ...

Burcon Chiropractic Launches Meniere’s Disease Treatment Clinical Trial in Grand Rapids

Burcon Chiropractic, in collaboration with the Meniere’s Research Institute, has announced the launch of a clinical trial ...
Business Wire

Sound Pharmaceuticals Receives FDA Breakthrough Therapy Designation for SPI-1005 to Treat Meniere’s Disease

SEATTLE--(BUSINESS WIRE)--Sound Pharmaceuticals (SPI) is pleased to announce that the FDA has granted its investigational new drug, SPI-1005, Breakthrough Therapy Designation (BTD) for the treatment ...

Contralateral endolymphatic hydrops ID'd in one in four patients with unilateral Meniere disease

For patients with unilateral Meniere disease, endolymphatic hydrops occur in 24.2% of contralateral ears, according to a study published online Feb. 4 in Acta Oto-Laryngologica.
Medical Xpress

Otorhinolaryngologic Diseases: News and Research on Meniere Disease

Nystagmus during vertigo attacks in patients with Meniere disease can be video-recorded with a mobile phone and provide a helpful therapeutic aid, according to a study published online Dec. 12 in the ...